secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001380106-26-000029
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct
--------------------------------------------------------------------------------

- Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).
- FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).
- FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.
- Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.
- Cash position $39M; $25M unused under Trinity Capital debt facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/0001380106-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010626000029/rpid-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001380106-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer